- Report
- January 2026
- 197 Pages
Global
From €3128EUR$3,545USD£2,707GBP
€3475EUR$3,939USD£3,007GBP
- Report
- January 2026
- 196 Pages
Global
From €3128EUR$3,545USD£2,707GBP
€3475EUR$3,939USD£3,007GBP
- Report
- February 2026
- 250 Pages
Global
From €3961EUR$4,490USD£3,428GBP
- Report
- May 2026
- 299 Pages
Global
From €5161EUR$5,850USD£4,466GBP
- Report
- February 2026
- 306 Pages
Global
From €2206EUR$2,500USD£1,909GBP
- Report
- October 2025
- 160 Pages
Global
From €2962EUR$3,358USD£2,563GBP
€3485EUR$3,950USD£3,016GBP
- Report
- July 2025
- 100 Pages
Global
From €3500EUR$4,250USD£3,135GBP
- Report
- February 2026
- 250 Pages
Global
From €3961EUR$4,490USD£3,428GBP
- Report
- June 2025
- 150 Pages
Global
From €3309EUR$3,750USD£2,863GBP
- Report
- June 2025
- 150 Pages
Global
From €2381EUR$2,699USD£2,061GBP
- Report
- February 2026
- 250 Pages
Global
From €3961EUR$4,490USD£3,428GBP
- Report
- February 2026
- 250 Pages
Global
From €3961EUR$4,490USD£3,428GBP
- Report
- May 2026
- 389 Pages
Global
From €5161EUR$5,850USD£4,466GBP
- Report
- January 2026
- 185 Pages
Global
From €3970EUR$4,500USD£3,436GBP
- Report
- July 2025
- 350 Pages
Global
From €4366EUR$4,949USD£3,778GBP
- Report
- October 2025
- 160 Pages
Global
From €2962EUR$3,358USD£2,563GBP
€3485EUR$3,950USD£3,016GBP
- Report
- August 2025
- 200 Pages
United States
From €2197EUR$2,490USD£1,901GBP
- Report
- May 2025
- 200 Pages
Global
From €2197EUR$2,490USD£1,901GBP
- Report
- August 2024
- 200 Pages
Global
From €2197EUR$2,490USD£1,901GBP
- Report
- December 2024
- 171 Pages
Global
From €3485EUR$3,950USD£3,016GBP

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions.
The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more